<DOC>
	<DOCNO>NCT01643590</DOCNO>
	<brief_summary>This randomize , double-blind , placebo control Phase II study design assess safety efficacy use JVS-100 treat heart failure .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy JVS-100 Administered Adults With Ischemic Heart Failure .</brief_title>
	<detailed_description>90 subject ischemic cardiomyopathy randomize receive single dose 15 30 mg JVS-100 matching placebo . Subjects randomize 1:1:1 receive either placebo , 15 mg 30 mg JVS-100 . Subjects monitor overnight 18-24 hour post dose schedule visit 3 day post-injection safety evaluation . All subject schedule follow-up visit approximately 30 day ( 1 month ) , 120 day ( 4 month ) , 360 day ( 12 month ) assess safety cardiac function .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<criteria>Willing able sign inform consent Greater equal 18 year age Subjects impaired 6 minute hall walk distance Impaired quality life measure Minnesota LWHF questionnaire Ischemic cardiomyopathy without acute coronary syndrome within last 6 month Residual welldemarcated region LV systolic dysfunction define least 3 consecutive segment abnormal wall motion echocardiography read echocardiography core laboratory LVEF ≤40 % measure echocardiography read echocardiography core laboratory Must meet wall thickness criterion Subject implant , functional AICD Subjects diabetes must ophthalmologist exam within last year show active proliferative retinopathy Subject receive stable optimal pharmacological therapy define : ACE inhibitor and/or ARB , Betablocker 90 day stable dose 30 day unless contraindicate Diuretic subject evidence fluid retention ASA unless contraindicate Statin unless contraindicate Aldosterone antagonist per physician discretion Planned revascularization within 30 day follow enrollment Estimated Glomerular Filtration Rate &lt; 30 ml/min* Signs acute heart failure within 24 hour schedule injection History aortic valve regurgitation classify `` moderate '' severe Moderate/Severe aortic stenosis define AVA &lt; 1.5 cm2 Note : Patient exclude patient 's medical record document within last 6 month patient either : aortic stenosis mild aortic stenosis normal aortic valve normal aortic pressure gradient aortic pressure gradient &lt; 20 mmHg Presence artificial aortic valve Subjects aortic aneurysm &gt; 3.8 cm Mitral regurgitation define `` severe '' measure echocardiography clinical site . Patients plan mitral valve repair replacement surgery Any patient history cancer exclude unless : The cancer limit curable nonmelanoma skin malignancy and/or The cancer remove successful tumor resection , without radiation chemotherapy treatment , 5 year prior enrollment study without recurrence Subjects must follow result age appropriate cancer screening : Subjects age 50 old Fecal occult blood test ( FOBT ) fecal immunochemical test ( FIT ) negative within last year Women age 30 old PAP test negative within last 3 year Women age 40 old mammogram negative within last year Men age 45 ProstateSpecific Antigen ( PSA ) blood test digital rectal examination ( DRE ) negative within last year At request site principal investigator , subject nonnegative result think due noncancerrelated condition evaluate medical monitor enrollment Exclusion Criteria ( ctd ) : Subjects persistent chronic atrial fibrillation exclude unless : A stable , regular heart rate maintain biventricular pacemaker A stable , regular heart rate maintain univentricular pacemaker pace less equal 40 % time Subjects Biventricular pace device implant within last 3 month OR previously implant Biventricular pace device programming plan reoptimized follow enrollment trial Previous solid organ transplant Subjects great 40 % univentricular RV Pacing Subjects uncontrolled diabetes define HbA1c &gt; 9.0 % Inability complete 6 minute walk treadmill exercise test Participation experimental clinical trial within 30 day prior enrollment Any subject enrol gene stem cell therapy cardiac trial within last year Life expectancy less 1 year Positive pregnancy test ( serum βHCG ) woman childbearing potential and/or unwillingness use contraceptives limit sexual activity describe Section 8.2.1 Unwillingness men capable father child agree use barrier contraception limit sexual activity describe Section 8.2.1 Subjects breast feeding Subjects positive test result hepatitis B/C and/or HIV Total Serum Bilirubin &gt; 4.0 mg/dl Aspartate aminotransferase ( AST ) &gt; 120 IU/L Alanine aminotransferase ( ALT ) &gt; 135 IU/L Alkaline phosphatase ( ALP ) &gt; 300 IU/L Clinically significant elevation PT PTT relative laboratory norm Any subject know exist LV thrombus LV thrombus detect screening period study . Subjects Rutherford class 5 6 critical limb ischemia Subject severe chronic obstructive pulmonary disease ( COPD ) Any subject requiring home oxygen use Subjects history Systemic Lupus Erythematosus ( SLE ) flare History drug alcohol abuse within last year A subject exclude he/she unfit trial base discretion site Principal Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>